The FDA has not found any evidence linking glucagon-like peptide 1 receptor agonist (GLP-1 RA) medications used for type 2 diabetes and obesity to suicidal thoughts or actions. This determination was made after reviewing clinical trial data and reports to the FDA Adverse Event Reporting System. While the agency cannot definitively rule out a small risk, ongoing investigation will continue, including an analysis of postmarketing data. Healthcare professionals are advised to continue following prescribing information for GLP-1 RAs and to monitor and counsel patients for any new or worsening depression, suicidal thoughts, or unusual changes in mood or behavior. Reporting of side effects involving GLP-1 RAs to the FDA MedWatch program is encouraged.
Source link
So Far, No Ties Between GLP-1s and Suicidal Thoughts
